<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01985373</url>
  </required_header>
  <id_info>
    <org_study_id>MD2012.02</org_study_id>
    <secondary_id>2012-005727-32</secondary_id>
    <nct_id>NCT01985373</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics and Safety of IVIG Nanogam 100 mg/ml</brief_title>
  <acronym>Nanogam</acronym>
  <official_title>Pharmacokinetics and Safety of the Intravenous Human Immunoglobulin Product Nanogam 100 mg/ml</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanquin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanquin</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Intravenous immunoglobulin (IVIG) is used for treatment of a heterogeneous group of immune
      related disorders both as immune-replacement and immune-modulating therapy. Sanquin developed
      a 100 mg/ml IVIg product (Nanogam 100 mg/ml). Patient will receive one infusion with Nanogam
      50 mg/ml as they used to (same dose) and subsequently 4 infusions with Nanogam 100 mg/ml
      (same dose). Aim is to show bioequivalency between the 50 mg/ml and the 100 mg/ml product of
      Sanquin.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>IgG trough levels</measure>
    <time_frame>before infusion</time_frame>
    <description>Comparison IVIG 5% and 10%</description>
  </primary_outcome>
  <primary_outcome>
    <measure>plasma concentration-time curve</measure>
    <time_frame>predose, 1 hour, 2 hours and 1, 2, 3, 7, 14 and 21 days post-dose</time_frame>
    <description>Comparison IVIG 5% and 10%</description>
  </primary_outcome>
  <primary_outcome>
    <measure>half-life</measure>
    <time_frame>predose, 1 hour, 2 hours and 1, 2, 3, 7, 14 and 21 days post-dose</time_frame>
    <description>Comparison IVIG 5% and 10%</description>
  </primary_outcome>
  <primary_outcome>
    <measure>area under the curve</measure>
    <time_frame>predose, 1 hour, 2 hours and 1, 2, 3, 7, 14 and 21 days post-dose</time_frame>
    <description>Comparison IVIG 5% and 10%</description>
  </primary_outcome>
  <primary_outcome>
    <measure>volume of distribution</measure>
    <time_frame>predose, 1 hour, 2 hours and 1, 2, 3, 7, 14 and 21 days post-dose</time_frame>
    <description>Comparison IVIG 5% and 10%</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>predose, 1 hour, 2 hours and 1, 2, 3, 7, 14 and 21 days post-dose</time_frame>
    <description>Comparison IVIG 5% and 10%</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax</measure>
    <time_frame>predose, 1 hour, 2 hours and 1, 2, 3, 7, 14 and 21 days post-dose</time_frame>
    <description>Comparison IVIG 5% and 10%</description>
  </primary_outcome>
  <primary_outcome>
    <measure>elimination rate constant(s)</measure>
    <time_frame>predose, 1 hour, 2 hours and 1, 2, 3, 7, 14 and 21 days post-dose</time_frame>
    <description>Comparison IVIG 5% and 10%</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>from first till 3 weeks after last infusion (11-19 weeks dependent on infusion frequency)</time_frame>
    <description>number and type</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Primary Immunodeficiency</condition>
  <arm_group>
    <arm_group_label>Intravenous immunoglobulin infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One intravenous infusion with Nanogam 50 mg/ml and 4 with Nanogam 100 mg/ml (0.2-0.8 g/kg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous immunoglobulin infusion</intervention_name>
    <description>Blood samples are drawn before infusion with Nanogam 50 and Nanogam 100 mg/ml and IgG levels are determined to study PK</description>
    <arm_group_label>Intravenous immunoglobulin infusion</arm_group_label>
    <other_name>Nanogam</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Primary a- or hypogammaglobulinemia, particularly patients with XLA or CVID

          -  Stabilised on treatment with Nanogam 50 mg/ml with 2-4 weeks intervals in an hospital
             or at home and willing to be treated with 1 infusion of Nanogam 50 mg/ml and 4
             infusions of Nanogam 100 mg/ml at the hospital

          -  A stable clinical situation (no activity of any other disease; a stable immunoglobulin
             dose and frequency)

          -  Age &gt;= 18 years

          -  The patient has signed the consent form

        Exclusion Criteria:

          -  Known with allergic reactions against human plasma or plasma products

          -  Having an ongoing progressive disease, including HIV infection

          -  Pregnancy or lactation

          -  Known with insufficiency of coronary or cerebral circulation

          -  Having renal insufficiency (plasma creatinin &gt; 115Âµmol/L)

          -  Having IgA deficiency and anti-IgA antibodies have been detected
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>F P Kroon, PhD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>LUMC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jeroen Bosch Ziekenhuis</name>
      <address>
        <city>Den Bosch</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMCG</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LUMC</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMC St. Radboud</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 31, 2013</study_first_submitted>
  <study_first_submitted_qc>November 8, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 15, 2013</study_first_posted>
  <last_update_submitted>April 3, 2015</last_update_submitted>
  <last_update_submitted_qc>April 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 6, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>intravenous immunoglobulin</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>10% IVIG</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>gamma-Globulins</mesh_term>
    <mesh_term>Rho(D) Immune Globulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

